trial
as of 2026-07-01A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication
NCTId NCT03557931
at a glance
Phase 2 · Completed
Enrollment 233 (actual)
Sponsored by Astellas Pharma Global Development, Inc.
Primary completion 2019-10-21
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
233 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2018-07-13
Primary completion
2019-10-21
Eligibility
ALL · 18 Years · 55 Years
Interventions & indications
Sponsors
Astellas Pharma Global Development, Inc.Lead Sponsor
Investigators
1
Executive Medical DirectorStudy Director
Sites
27 total
Cerritos, United StatesGarden Grove, United StatesLemon Grove, United StatesOakland, United StatesPico Rivera, United StatesSan Diego, United StatesSan Diego, United StatesSan Diego, United StatesTorrance, United StatesAtlanta, United StatesAtlanta, United StatesChicago, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
233
Phase
PHASE2
Primary Completion Date
2019-10-21
Status
COMPLETED
relationships
The graph out of here
drug
drug
drug
drug
drug
drug
drug
drug
drug
lead_sponsor
indication
indication
indication
investigator